Analytical Data
-
Gene name
SLC22A12
- Application
-
Alternative Names
OATL4; URAT1
-
Species
Human
-
Source
HEK293
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96S37-1
-
Expression Region
A2-F553
-
Protein Length
Partial
-
Molecular Weight
60.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC22A12, also known as urate transporter 1 (URAT1), is a member of the solute carrier family, primarily responsible for the reabsorption of uric acid in the kidneys. Dysregulation of SLC22A12 has been implicated in various diseases, particularly gout and hyperuricemia, making it a crucial target for therapeutic interventions. Given this biological significance, the study of SLC22A12 recombinant protein has gained momentum in recent years. Researchers are focused on characterizing its structure, function, and role in uric acid homeostasis. Recombinant SLC22A12 can be produced using various expression systems, allowing for detailed studies of its transport mechanisms and interactions with uric acid as well as other potential substrates. High-throughput screening of small molecules that can modulate SLC22A12 activity may lead to novel treatments for conditions associated with elevated uric acid levels. Furthermore, understanding polymorphisms within the SLC22A12 gene can provide insights into individual variations in uric acid metabolism, paving the way for personalized medicine approaches. Overall, the investigation of SLC22A12 recombinant protein is a promising area of research that holds potential for advancing our understanding of renal transport processes and developing new strategies for managing hyperuricemic disorders.
